J Cancer 2018; 9(22):4099-4107. doi:10.7150/jca.27408 This issue Cite

Research Paper

Immunoscore System for Predicting Clinical Outcome of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors

Jia-Xi Yao*, Xiang Chen*, Wei Xi, Yan-Jun Zhu, Hang Wang, Xiao-Yi Hu, Jian-Ming Guo

Department of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
*Jia-Xi Yao and Xiang Chen contributed equally to the work.

Citation:
Yao JX, Chen X, Xi W, Zhu YJ, Wang H, Hu XY, Guo JM. Immunoscore System for Predicting Clinical Outcome of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors. J Cancer 2018; 9(22):4099-4107. doi:10.7150/jca.27408. https://www.jcancer.org/v09p4099.htm
Other styles

File import instruction

Abstract

We conducted this study to determine whether immunoscore system (IS) predicts survival in patients with metastatic renal cell carcinoma (mRCC). A total of 218 mRCC patients treated with sunitinib or sorafenib in Zhongshan Hospital, Fudan University were recruited during 2007-2017, retrospectively. CD8, CD4, Treg, PD-1 and PD-L1 expression were evaluated by immunohistochemical staining of paraffin embedded slide. Kaplan-Meier method and COX regression model were used in survival analyses. Multivariate analyses demonstrated that expressions of CD8, Treg, PD-1 and stromal PD-L1 (sPD-L1) expressions were independent predictive factors for OS, thus IS was established containing these four immunological factors. Subsequent analysis revealed that performance of IS provided good differentiation of OS and PFS. Besides, multivariate analysis identified IS as an independent prognostic factor for OS (p<0.001) and PFS (p=0.002). IS, compared with International mRCC Database Consortium (IMDC) risk model, and provided better prediction ability for OS. Results suggested that IS was a powerful prognostic factor for OS and PFS in patients with mRCC treated with tyrosine kinase inhibitors. And IS can be used as essential supplement to IMDC for outcome prediction in mRCC patients.

Keywords: immunoscore system, renal cell carcinoma, tyrosine kinase inhibitors, prognostic factor


Citation styles

APA
Yao, J.X., Chen, X., Xi, W., Zhu, Y.J., Wang, H., Hu, X.Y., Guo, J.M. (2018). Immunoscore System for Predicting Clinical Outcome of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors. Journal of Cancer, 9(22), 4099-4107. https://doi.org/10.7150/jca.27408.

ACS
Yao, J.X.; Chen, X.; Xi, W.; Zhu, Y.J.; Wang, H.; Hu, X.Y.; Guo, J.M. Immunoscore System for Predicting Clinical Outcome of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors. J. Cancer 2018, 9 (22), 4099-4107. DOI: 10.7150/jca.27408.

NLM
Yao JX, Chen X, Xi W, Zhu YJ, Wang H, Hu XY, Guo JM. Immunoscore System for Predicting Clinical Outcome of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors. J Cancer 2018; 9(22):4099-4107. doi:10.7150/jca.27408. https://www.jcancer.org/v09p4099.htm

CSE
Yao JX, Chen X, Xi W, Zhu YJ, Wang H, Hu XY, Guo JM. 2018. Immunoscore System for Predicting Clinical Outcome of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors. J Cancer. 9(22):4099-4107.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.